TLDR Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
A case study described a man in his 40s with chronic graft-versus-host disease (cGVHD) and alopecia universalis following an allogenic hematopoietic stem cell transplantation. The patient was treated with ruxolitinib, starting at 5 mg every 12 hours and increasing to 10 mg every 12 hours. Over 10 months, the patient showed marked hair regrowth on the scalp and face, as well as improvement in liver function tests and skin cGVHD symptoms. This case suggested that ruxolitinib could be a potential therapy for patients with cGVHD and alopecia universalis, although further studies were needed to confirm these findings.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
27 citations,
September 2014 in “JAMA dermatology” Female donor to male recipient sex mismatch and positive ACA-IgG are key risk factors for vitiligo and alopecia areata in chronic GvHD patients.
[object Object]
13 citations,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
30 citations,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
1 citations,
January 2017 in “International journal of trichology” Diphenylcyclopropenone (DPCP) effectively treated both alopecia areata and verruca vulgaris.
[object Object] 
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
